Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AGEN | AGENUS INC | 2026-10-15 14:33:46 | 6.79 | 0.33 | 5.02 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGEN | 0001098972 | AGENUS INC | US00847G8042 | 529900NDQQGU5H4UJK81 | 061562417 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 3 FORBES ROAD | LEXINGTON | MA | 02421 | UNITED STATES | US | 781-674-4410 | 3 FORBES ROAD, LEXINGTON, MA, 02421 | 3 FORBES ROAD, LEXINGTON, MA, 02421 | ANTIGENICS INC /DE/ | Biotechnology | 1994 | Garo H. Armen | — | http://www.agenusbio.com | 135,400,000 | 42,615,618 | 45,020,407 | Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. | 2026-10-09 03:46:21 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 135,400,000 | -216,200,000 | -61.4903 | 38,398,354 | 13,089,513 | 51.7191 |
| 2024 | 351,600,000 | -231,900,000 | -39.7429 | 25,308,841 | -393,611,230 | -93.9586 |
| 2023 | 583,500,000 | 39,400,000 | 7.2413 | 418,920,071 | 86,406,796 | 25.986 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christine M. Klaskin | Vice President | 2025 | 298,224 | 0 | — | — | 6,538 | 332,019 |
| Garo H. Armen | Chief Executive Officer | 2025 | 715,260 | 429,156 | — | — | 64,909 | 1,350,325 |
| Steven J. O’Day | Chief Medical Officer | 2025 | 594,880 | 297,440 | — | — | 10,500 | 902,820 |
| Steven J. O’Day | Chief Medical Officer | 2024 | 594,880 | 0 | 0 | — | 10,350 | 968,491 |
| Garo H. Armen | Chief Executive Officer | 2024 | 715,260 | 0 | 0 | — | 56,377 | 3,717,621 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 81 |
| 2024 | 316 |
| 2023 | 389 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 114,196,000 | 103,463,000 | 156,314,000 |
| Cost Of Revenue | 1,022,000 | 486,000 | 3,111,000 |
| Gross Profit | 113,174,000 | 102,977,000 | 153,203,000 |
| Research And Development Expenses | 79,338,000 | 155,528,000 | 234,569,000 |
| General And Administrative Expenses | 54,392,000 | 71,878,000 | 78,739,000 |
| Operating Expenses | 133,343,000 | 223,452,000 | 312,752,000 |
| Operating Income | -20,169,000 | -120,475,000 | -159,549,000 |
| Net Income | -3,083,000 | -232,271,000 | -257,437,000 |
| Earnings Per Share Basic | 0 | -10.59 | -0.69 |
| Earnings Per Share Diluted | 0 | -10.59 | -0.69 |
| Weighted Average Shares Outstanding Basic | 29,734,000 | 21,473,000 | 357,889,000 |
| Weighted Average Shares Outstanding Diluted | 29,734,000 | 21,473,000 | 357,889,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,998,000 | 40,437,000 | 76,110,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,831,000 | 407,000 | 800,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,089,000 | 2,415,000 | 2,372,000 |
| Total Assets Current | 133,436,000 | 45,574,000 | 112,416,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 15,470,000 | 120,087,000 | 133,421,000 |
| Other Assets Non Current | 3,307,000 | 5,834,000 | 9,336,000 |
| Total Assets Non Current | 18,777,000 | 125,921,000 | 142,757,000 |
| Total Assets | 226,798,000 | 226,271,000 | 313,913,000 |
| Accounts Payable | 82,987,000 | 61,470,000 | 61,446,000 |
| Deferred Revenue | 0 | 31,000 | 18,000 |
| Short Term Debt | 44,655,000 | 2,698,000 | 146,000 |
| Other Liabilities Current | 529,000 | 7,817,000 | 13,915,000 |
| Total Liabilities Current | 323,489,000 | 221,401,000 | 255,897,000 |
| Long Term Debt | 44,655,000 | 33,171,000 | 12,768,000 |
| Other Liabilities Non Current | 259,000 | 738,000 | 5,420,000 |
| Total Liabilities Non Current | 174,420,000 | 331,250,000 | 218,347,000 |
| Total Liabilities | 497,909,000 | 552,651,000 | 474,244,000 |
| Common Stock | 353,000 | 236,000 | 3,944,000 |
| Retained Earnings | -2,182,765,000 | -2,182,880,000 | -1,955,668,000 |
| Accumulated Other Comprehensive Income | -439,000 | -1,398,000 | -955,000 |
| Total Shareholders Equity | -271,111,000 | -326,380,000 | -160,331,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 9,999,000 | 13,343,000 | 13,588,000 |
| Share Based Compensation Expense | 13,770,000 | 17,390,000 | 22,869,000 |
| Other Non Cash Income Expense | -2,954,000 | — | — |
| Change In Accounts Receivable | 1,728,000 | -25,344,000 | 23,461,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 23,500,000 | 2,013,000 | 21,366,000 |
| Change In Other Liabilities | 198,000 | 691,000 | 1,545,000 |
| Cash From Operating Activities | -77,195,000 | -158,315,000 | -224,202,000 |
| Purchases Of Marketable Securities | 0 | — | 14,647,000 |
| Sales Of Marketable Securities | 0 | — | 30,000,000 |
| Acquisition Of Property Plant And Equipment | 6,000 | 576,000 | 9,954,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 1,194,000 | 27,000 | 3,400,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 36,136,000 | 33,023,000 | 133,157,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 12,500,000 | 20,000,000 | — |
| Repayment Of Long Term Debt | 2,500,000 | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 36,593,000 | 122,840,000 | 119,866,000 |
| Change In Cash | -39,361,000 | -35,708,000 | -101,564,000 |
| Cash At End Of Period | 2,998,000 | 40,437,000 | 76,110,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 1,175,000 | 2,278,000 | 3,168,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0 | -10.59 | -0.69 |
| Price To Earnings Ratio | — | -0.2587 | -23.9971 |
| Earnings Growth Rate | -100 | 1,434.7826 | -11.5385 |
| Price Earnings To Growth Ratio | — | -0.0002 | 2.0797 |
| Book Value Per Share | -9.1179 | -15.1996 | -0.448 |
| Price To Book Ratio | -0.3444 | -0.1803 | -36.9606 |
| Ebitda | 62,534,000 | -98,507,000 | -243,849,000 |
| Enterprise Value | 179,676,760 | 54,268,020 | 5,862,730,062 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.3294 | -0.1099 | -0.0805 |
| Capital Expenditures | -94,618,000 | 9,000 | 13,992,000 |
| Free Cash Flow | 17,423,000 | -158,324,000 | -238,194,000 |
| Return On Equity | 0.0114 | 0.7117 | 1.6057 |
| One Year Beta | 1.4429 | 2.7415 | 1.5384 |
| Three Year Beta | 1.7446 | 1.923 | 1.66 |
| Five Year Beta | 1.7145 | 1.3038 | 1.1984 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| HARRISON THOMAS L | Director | 2026-10-01 | 4,443 | A | 51,988 |
| Wright Timothy | Director | 2026-10-01 | 1,178 | A | 29,807 |
| ARMEN GARO H | Director | 2026-08-10 | 1,971,500 | A | 1,971,500 |
| Buell Jennifer | Director | 2026-08-05 | 200,000 | A | 200,000 |
| Hirsch Susan B | Director | 2026-08-05 | 50,000 | A | 50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Fortitude Family Office, LLC | 2026-09-30 | 596 | 60 | 9.9333 |
| Essential Partners LLC | 2026-09-30 | 248 | 25 | 9.92 |
| Post Resch Tallon Group Inc. | 2026-09-30 | 126,608 | 12,750 | 9.93 |
| Farther Finance Advisors, LLC | 2026-09-30 | 139 | 14 | 9.9286 |
| GAMMA Investing LLC | 2026-09-30 | 7,815 | 787 | 9.9301 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TARGET PORTFOLIO TRUST | 2026-07-31 | Class R4 | PSVKX | 39,500 | 296,250 | 0.0682 |
| TARGET PORTFOLIO TRUST | 2026-07-31 | Class R2 | PSVDX | 39,500 | 296,250 | 0.0682 |
| TARGET PORTFOLIO TRUST | 2026-07-31 | Class C | TRACX | 39,500 | 296,250 | 0.0682 |
| TARGET PORTFOLIO TRUST | 2026-07-31 | Class R6 | TSVQX | 39,500 | 296,250 | 0.0682 |
| TARGET PORTFOLIO TRUST | 2026-07-31 | Class A | TSVAX | 39,500 | 296,250 | 0.0682 |